At Trevena, our mission is to deliver innovative solutions to patients and healthcare providers confronting serious medical conditions. Our lead product candidate is oliceridine (TRV130), an innovative new chemical entity currently in Phase 3 clinical trials for the management of moderate-to-severe acute pain. Based on the results of our earlier clinical trials, oliceridine was designated a Breakthrough Therapy by the U.S. Food and Drug Administration. We also have discovered several other product candidates with the potential to address problems across a wide range of therapeutic areas, including moderate-to-severe acute and chronic pain, and acute episodic migraine. In addition, we have an early-stage portfolio of drug discovery programs currently in lead optimization.
Our history is rooted in strong science – Trevena was founded to translate Nobel Prize-winning research into a new generation of groundbreaking medicines. Our novel approach to drug discovery has established us as pioneers in acute care medicine.